Yandong He, Xuhong Huang, Xiaoxia Li, Hongwei Liu, Min Liu, Junjia Tao, Yuanzhou Shan, Hafiz Khuram Raza, Yanqiu Liu, Wenting Zhong, Xue-Ping Cao, Yuan-Yuan Yang, Ruimei Li, Xian-Long Fang, Kang-Jian Zhang, Rong Zhang, Feng Liu
OBJECTIVE: To evaluate the safety and preliminary efficacy of YSCH-01 (Recombinant L-IFN adenovirus) in subjects with advanced solid tumors. METHODS: In this single-center, open-label, investigator-initiated trial of YSCH-01, 14 patients with advanced solid tumors were enrolled. The study consisted of two distinct phases: (1) the dose escalation phase and (2) the dose expansion phase; with three dose groups in the dose escalation phase based on dose levels (5.0×109 viral particles (VP)/subject, 5...
May 7, 2024: Journal for Immunotherapy of Cancer